{"id":5378,"date":"2025-12-17T22:22:32","date_gmt":"2025-12-17T19:22:32","guid":{"rendered":"https:\/\/dmdwarrior.com\/?p=5378"},"modified":"2025-12-17T22:33:23","modified_gmt":"2025-12-17T19:33:23","slug":"satellos-sat-3247-phase-2-basecamp-clinical-trial-nct07287189","status":"publish","type":"post","link":"https:\/\/dmdwarrior.com\/tr\/satellos-sat-3247-phase-2-basecamp-clinical-trial-nct07287189\/","title":{"rendered":"Satellos, Duchenne Kas Distrofisi Olan Y\u00fcr\u00fcyen Hastalarda SAT-3247'nin Faz 2A (BASECAMP) \u00c7al\u0131\u015fmas\u0131n\u0131n Ba\u015flad\u0131\u011f\u0131n\u0131 Duyurdu"},"content":{"rendered":"<p class=\"wp-block-paragraph\">Satellos, 7 ila 10 ya\u015f aras\u0131 ayakta tedavi g\u00f6ren Duchenne kas distrofisi hastalar\u0131nda SAT-3247&#039;nin (NCT07287189) Faz 2A \u00e7al\u0131\u015fmas\u0131n\u0131n ba\u015flat\u0131ld\u0131\u011f\u0131n\u0131 duyurdu. Bu \u00e7al\u0131\u015fmada, SAT-3247&#039;nin iki dozu, optimal dozu, g\u00fcvenli\u011fi, tolerans\u0131 ve \u00f6n etkinli\u011fi belirlemek amac\u0131yla, randomize, \u00e7ift k\u00f6r, plasebo kontroll\u00fc, haftal\u0131k uygulama rejimiyle 12 hafta boyunca incelenecektir. <strong>Daha fazla bilgi edin<\/strong>: <a href=\"https:\/\/dmdwarrior.com\/tr\/satellos-receives-fda-and-international-clearance-to-commence-pediatric-phase-2-testing-of-sat-3247-for-duchenne-muscular-dystrophy\/\" target=\"_blank\" rel=\"noreferrer noopener\">Satellos, Duchenne Musk\u00fcler Distrofisi i\u00e7in SAT-3247&#039;nin Pediatrik Faz 2 Testine Ba\u015flamak \u0130\u00e7in FDA ve Uluslararas\u0131 Onay Ald\u0131<\/a><\/p>\n\n\n\n<div class=\"wp-block-rank-math-toc-block\" id=\"rank-math-toc\"><h2>\u0130\u00e7indekiler<\/h2><nav><ul><li><a href=\"#what-is-sat-3247-phase-2-a-clinical-trial\">SAT-3247 Faz 2A Klinik \u00c7al\u0131\u015fmas\u0131 nedir?<\/a><\/li><li><a href=\"#rag-18-sa-rna-early-phase-1-nct-07282652\">SAT-3247 Faz 2A \u2013 NCT07287189<\/a><\/li><li><a href=\"#how-to-participate-in-the-wve-n-531-clinical-trial\">SAT-3247 Faz 2A Klinik \u00c7al\u0131\u015fmas\u0131na Nas\u0131l Kat\u0131labilirsiniz?<\/a><\/li><\/ul><\/nav><\/div>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"what-is-sat-3247-phase-2-a-clinical-trial\">SAT-3247 Faz 2A Klinik \u00c7al\u0131\u015fmas\u0131 nedir?<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Bu, 7 ila 10 ya\u015f aras\u0131 ayakta tedavi g\u00f6ren DMD hastalar\u0131nda SAT-3247&#039;nin k\u00fcresel bir faz 2a denemesidir. Deneme, optimal dozu, g\u00fcvenli\u011fi, tolerans\u0131 ve \u00f6n etkinli\u011fi belirlemek i\u00e7in 12 hafta boyunca randomize, \u00e7ift k\u00f6r, plasebo kontroll\u00fc hafta i\u00e7i rejiminde iki farkl\u0131 SAT-3247 dozunu inceleyecektir. ABD ve Kanada&#039;da tek doz SAT-3247 ve plasebo; \u0130ngiltere, AB, S\u0131rbistan ve Avustralya&#039;da ise iki doz SAT-3247 ve plasebo incelenecektir.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">D\u00fcnya genelinde, 7 ila 10 ya\u015f aras\u0131 ayakta tedavi g\u00f6ren en fazla 51 DMD hastas\u0131n\u0131n kayd\u0131 planlanmaktad\u0131r. Rastgele atama, ba\u015flang\u0131\u00e7taki kortikosteroid rejimi ve daha \u00f6nce kullan\u0131lan DMD e\u015flik eden ila\u00e7lar dikkate al\u0131narak tabakaland\u0131r\u0131lacakt\u0131r.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Her kat\u0131l\u0131mc\u0131 12 hafta boyunca g\u00fcnde bir kez SAT-3247 veya e\u015fde\u011fer plasebo dozu alacakt\u0131r.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Kat\u0131l\u0131mc\u0131lar, ara\u015ft\u0131rma \u00fcr\u00fcn\u00fcn\u00fcn dozlamas\u0131na ba\u015flanmadan 28 g\u00fcn \u00f6nce ba\u015flang\u0131\u00e7 a\u015famas\u0131nda (Baseline) taramadan ge\u00e7irilecektir. Tarama d\u00f6neminin ard\u0131ndan kat\u0131l\u0131mc\u0131lar, ba\u015flang\u0131\u00e7 ziyaretini (Ziyaret 2), 1. haftada bir takip telefon g\u00f6r\u00fc\u015fmesini ve 4. haftada (Ziyaret 3), 8. haftada (Ziyaret 4) ve 12. haftada (Ziyaret 5) ziyaretleri tamamlayacaklard\u0131r.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"rag-18-sa-rna-early-phase-1-nct-07282652\">SAT-3247 Faz 2A \u2013 NCT07287189<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Ayakta tedavi g\u00f6ren DMD hastalar\u0131nda a\u011f\u0131zdan uygulanan SAT-3247&#039;nin doz kar\u015f\u0131la\u015ft\u0131rmas\u0131 ve ke\u015fifsel etkinlik \u00e7al\u0131\u015fmas\u0131 olan Faz 2a, randomize, \u00e7ift k\u00f6r, plasebo kontroll\u00fc bir \u00e7al\u0131\u015fma.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong><strong>\u00c7al\u0131\u015fma Ba\u015flang\u0131c\u0131 (Ger\u00e7ek)<\/strong><\/strong>: 2025-12-08<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Birincil Tamamlanma (Tahmini)<\/strong>: 2026-03-31<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>\u00c7al\u0131\u015fman\u0131n Tamamlanmas\u0131 (Tahmini)<\/strong>: 2026-06-30<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Kat\u0131l\u0131mc\u0131 Say\u0131s\u0131 (Tahmini)<\/strong>: 51<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>\u00c7al\u0131\u015fma T\u00fcr\u00fc<\/strong>: M\u00fcdahaleci<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Konum<\/strong>: ABD, Avustralya, Kanada, S\u0131rbistan, Birle\u015fik Krall\u0131k<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>\u00c7al\u0131\u015fmaya Uygun Ya\u015flar<\/strong>: 7-9 Ya\u015f Aras\u0131 (Erkek \u00c7ocuk)<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Temel dahil etme ve hari\u00e7 tutma kriterleri. \u2013\u00a0<a href=\"https:\/\/clinicaltrials.gov\/study\/NCT07287189\" target=\"_blank\" rel=\"noreferrer noopener\">NCT07287189<\/a>\u00a0\u2013<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"how-to-participate-in-the-wve-n-531-clinical-trial\">SAT-3247 Faz 2A Klinik \u00c7al\u0131\u015fmas\u0131na Nas\u0131l Kat\u0131labilirsiniz?<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">SAT-3247 Faz 2A klinik \u00e7al\u0131\u015fmas\u0131na kat\u0131lmak i\u00e7in a\u015fa\u011f\u0131daki ileti\u015fim bilgilerini kullanabilirsiniz.\u00a0<strong>Daha fazla bilgi edin<\/strong>:\u00a0<a href=\"https:\/\/dmdwarrior.com\/tr\/how-to-participate-in-clinical-trials-for-duchenne\/\" target=\"_blank\" rel=\"noreferrer noopener\">Duchenne (DMD) \u0130\u00e7in Klinik Ara\u015ft\u0131rmalara Nas\u0131l Kat\u0131labilirsiniz?<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\u00c7al\u0131\u015fmaya kat\u0131l\u0131m hakk\u0131nda sorular\u0131 yan\u0131tlayabilecek ki\u015filerin ileti\u015fim bilgileri ve \u00e7al\u0131\u015fman\u0131n nerede y\u00fcr\u00fct\u00fcld\u00fc\u011f\u00fcne dair bilgiler yay\u0131nlanacakt\u0131r.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Devam\u0131n\u0131 oku<\/strong>:&nbsp;<a href=\"https:\/\/dmdwarrior.com\/tr\/dmd-therapies\/\" target=\"_blank\" rel=\"noreferrer noopener\">Duchenne \u0130\u00e7in Klinik Ara\u015ft\u0131rmalar (T\u00fcm Ara\u015ft\u0131rmalar\u0131n Listesi)<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>Satellos announced the commencement of a Phase 2A trial of SAT-3247 (NCT07287189) in ambulatory patients with Duchenne aged 7 to 10 years. In this trial, two doses of SAT-3247 will be studied over 12 weeks in a randomized, double-blind, placebo-controlled, intraweek regimen to determine the optimal dose, safety, tolerance, and preliminary efficacy. Learn More: Satellos [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":5381,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[27],"tags":[171,303,137,242,470,251,252,253],"class_list":["post-5378","post","type-post","status-publish","format-standard","has-post-thumbnail","category-research","tag-canada","tag-cell-therapy","tag-clinical-trial","tag-clinical-trials","tag-nct07287189","tag-sat-3247","tag-satellos","tag-satellos-bioscience"],"_links":{"self":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts\/5378","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/comments?post=5378"}],"version-history":[{"count":0,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts\/5378\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/media\/5381"}],"wp:attachment":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/media?parent=5378"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/categories?post=5378"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/tags?post=5378"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}